US › Healthcare

Aptevo Therapeutics Inc (APVO)

US · Healthcare · Biotechnology

$1.84+6.98%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-6.4M

EPS

$-5.31

EPS estimate

$-6.02

EPS came in at -5.31 against a street estimate of -6.02 — a beat of 11.8%.

Key statistics

Market cap

$3.3M

P/E

0.0

Forward P/E

3.9

P/B

0.54

Book value

$4.26

EPS (TTM)

$456.62

52-week high

$48.78

52-week low

$1.37

50-day MA

$3.48

200-day MA

$7.02

Beta

1.61

Analyst view

Analysts rate Aptevo Therapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $25.50.

Shareholding

Insiders

4.15%

Institutions

2.88%

Largest institutional holders

Fund	Stake
GSA Capital Partners LLP	1.19%
Geode Capital Management, LLC	0.74%
Vanguard Capital Management, LLC	0.70%
Vanguard Fiduciary Trust Co	0.23%
UBS Group AG	0.19%
Advisor Group Holdings, Inc.	0.02%
SBI Securities Co Ltd	0.01%
CWM, LLC duplicate	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aptevo Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.